Alerts will be sent to your verified email
Verify EmailASTRAZEN
|
Astrazeneca Pharma I
|
Natco Pharma
|
Pfizer
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
18.6 % | 31.2 % | 5.2 % |
|
R&D as a % of Total Sales
|
0.0 | 9.1 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
17.42 % | 15.58 % | 19.03 % |
|
5yr average Equity Multiplier
|
1.99 | 1.17 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.91 | 0.48 | 0.6 |
|
5yr Avg Net Profit Margin
|
9.65 % | 26.79 % | 26.04 % |
|
Price to Book
|
26.22 | 2.26 | 5.66 |
|
P/E
|
104.3 | 12.58 | 25.53 |
|
5yr Avg Cash Conversion Cycle
|
-6.33 Days | 4.27 Days | 21.86 Days |
|
Inventory Days
|
68.19 Days | 91.91 Days | 49.93 Days |
|
Days Receivable
|
35.81 Days | 93.3 Days | 29.1 Days |
|
Days Payable
|
187.52 Days | 134.54 Days | 77.28 Days |
|
5yr Average Interest Coverage Ratio
|
142.38 | 60.49 | 185.18 |
|
5yr Avg ROCE
|
23.84 % | 19.09 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
14.57 % | 34.0 % | 31.72 % |
|
5 yr average Debt to Equity
|
0.0 | 0.06 | 0.0 |
|
5yr CAGR Net Profit
|
4.4 % | 33.73 % | 76.68 % |
|
5yr Average Return on Assets
|
8.92 % | 13.46 % | 15.25 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 49.42 % | 63.92 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.58 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
4.44 % | -6.78 % | 5.56 % |
|
Astrazeneca Pharma I
|
Natco Pharma
|
Pfizer
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|